Abstract
Objective
Mitochondrial oxidative stress is the basis for pancreatic β-cell apoptosis and a common pathway for numerous types of damage, including glucotoxicity and lipotoxicity. We cultivated mice pancreatic β-cell tumor Min6 cell lines in vitro and observed pancreatic β-cell apoptosis and changes in mitochondrial function before and after the addition of Exendin-4. Based on these observations, we discuss the protective role of Exendin-4 against mitochondrial oxidative damage and its relationship with Ca2+-independent phospholipase A2.
Methods
We established a pancreatic β-cell oxidative stress damage model using Min6 cell lines cultured in vitro with tert-buty1 hydroperoxide and hydrogen peroxide. We then added Exendin-4 to observe changes in the rate of cell apoptosis (Annexin-V-FITC-PI staining flow cytometry and DNA ladder). We detected the activity of the caspase 3 and 8 apoptotic factors, measured the mitochondrial membrane potential losses and reactive oxygen species production levels, and detected the expression of cytochrome c and Smac/DLAMO in the cytosol and mitochondria, mitochondrial Ca2-independent phospholipase A2 and Ca2+-independent phospholipase A2 mRNA.
Results
The time-concentration curve showed that different percentages of apoptosis occurred at different time-concentrations in tert-buty1 hydroperoxide- and hydrogen peroxide-induced Min6 cells. Incubation with 100 µmol/l of Exendin-4 for 48 hours reduced the Min6 cell apoptosis rate (p<0.05). The mitochondrial membrane potential loss and total reactive oxygen species levels decreased (p<0.05), and the release of cytochrome c and Smac/DLAMO from the mitochondria was reduced. The study also showed that Ca2+-independent phospholipase A2 activity was positively related to Exendin-4 activity.
Conclusion
Exendin-4 reduces Min6 cell oxidative damage and the cell apoptosis rate, which may be related to Ca2-independent phospholipase A2.
Introduction
Changes in mitochondrial function and structure constitute the basis of pancreatic β-cell apoptosis and are a fundamental cause of insulin resistance. The long-term metabolic load, including hyperglycemia and hyperlipidemia, causes pancreatic β-cell mitochondrial superoxide (ROS) to accumulate and the mitochondria to enlarge. Inner membrane pores are formed, and cytochrome c is released from mitochondrial inner membranes into the cytoplasm. This release activates a series of apoptosis factors, including caspase 3, 6, 7, 8 and 9, and results in DNA fragmentation, protein denaturation, membrane phospholipid oxidation and increased apoptosis. Simultaneously, because of the mitochondrial fatty acid oxidation barrier and increased intracellular acyl-coenzyme A and acylglycerol levels, an insulin-mediated glucose transport key signal is activated and glucose transport is blocked, which leads to insulin resistance [1]–[5].
Cardiolipin is a major component of the mitochondrial inner membrane. Cardiolipin possesses a unique dimer structure with two negative charges and four fatty acyl groups that easily combine with ROS and produce an oxidative reaction; therefore, cardiolipin is a target of oxidative damage [6]–[8]. Ca2+-independent Phospholipase A2 (iPLA-2) is located within the mitochondrial inner membrane and is an important substance for remodeling and damage repair and for assisting and accelerating apoptosis and the clearance of damaged cells [9]–[15].
Exendin-4 is an analog of glucagon-like peptide-1(GLP-1). It promotes insulin gene transcription, synthesis and secretion; inhibits the apoptosis of pancreatic β-cells at the gene level; and promotes proliferation and regeneration. Currently, Exendin-4 is a relatively common anti-diabetic drug in application and research. Exendin-4 is also the only drug that can theoretically delay and reverse the development of diabetes [16]–[22].
In the present study, mice pancreatic β-cell tumor Min6 cell lines were cultured in vitro, and pancreatic β-cell apoptosis and changes in mitochondrial function were observed before and after the application of Exendin-4. In this paper, the protective role of Exendin-4 in the diabetic mitochondrial function barrier and the relationship between this role and iPLA-2 are discussed.
Research Methods
We used mice pancreatic β-cell tumor Min6 cell lines (the primary culture cell came from the Shanghai Institute of Biological Products and passed to 30 generations), high-glucose medium (DMEM) and 15% fetal calf serum. We performed in vitro cultivation at 37°C and 5% CO2 and used different concentrations of tert-buty1 hydroperoxide (t-BHP) and H2O2 to establish a cell oxidative damage model.
Groups
Different intervention groups were established based on time-concentrations. The t-BHP groups were divided into the following subgroups based on intervention time: 30, 45 and 60 min and 4, 8, 12 and 24 hours. The intervention concentrations were 0, 50, 100, 125, 200 and 400 µmol/l. The H2O2 group intervention times were 4, 8, 12 and 24 hours with concentrations of 0, 50, 100 and 200 µmol/l.
Determination of the apoptosis rate
Two methods were adopted to detect the cell apoptosis rate and determine the best intervention time and concentration.
Initially, Annexin-V-FITC-PI apoptosis detection assay kits (Sigma, Saint Louis, Missouri, USA) were used to confirm the best intervention time-concentration. Annexin V is a sensitivity index used to detect early cell apoptosis. Propidium iodide (PI) permeates the cell membrane and dyes cell nuclei red during the middle and later stages of apoptosis and in dead cells, thus distinguishing cells at different apoptotic stages.
We inoculated Min6 cells in a six-well cell culture plate; each well contained approximately 1×106 cells. The groups were divided based on time-concentration. After each reaction with each tBHP concentration was allowed to proceed for the allotted time, the cells were harvested, counted and washed with cold phosphate buffered saline (PBS) and digested with pancreatic enzymes. Annexin-V-FITC and PI were used for staining following the manufacturer's staining procedure (SIGMA Annexin V-FITC Apoptosis Detection Kit). Flow cytometry was used for detection (Becton Dickinson, FACScan), and Cell Quest TM software was used to analyze the results. On the scatter chart of the dual-variable flow cytometry, the lower left quadrant displayed living cells (FITC−/PI−), the upper left quadrant displayed necrotic cells (FITC−/PI+), the right upper quadrant displayed late-stage apoptotic cells (FITC+/PI+) and the right lower quadrant displayed early-stage apoptotic cells (FITC+/PI−). Simultaneously, four comparison groups were established: a blank control, which contained normal cells without dyes or treatments; normal cells with AV-FITC (used for the horizontal axis to confirm and distinguish the four quadrants); normal cells with PI (used to confirm the vertical axis); and normal cells with both dyes added. The experiment was repeated three times.
DNA fragment analysis
The most prominent feature and biochemical characteristic of cell apoptosis is the degradation of DNA into oligonucleotide fragments, which are composed of approximately 180–200 bp, or DNA polymers, and agarose gel electrophoresis reveals a characteristic ladder-shaped belt. Based on the biochemical characteristics of cell apoptosis described above, an Apoptotic DNA Ladder Kit (Roche Applied Science, Mannheim, Germany) was used to detect apoptosis.
Each well was inoculated with 2×106 Min6 cells washed with cold PBS, digested with 0.25% pancreatic enzymes for 1 min and repeatedly blown with cold PBS. The cells were centrifuged twice at 200 g for 5 min; then, 200 µl of binding buffer was added, and the cells were incubated at room temperature (15–25°C) for 10 min. Altogether, 100 µl of isopropyl alcohol was added, and the cells were centrifuged twice at 8,000 g for 1 min. The cells were repeatedly centrifuged at 13,000 g for 1 min and placed in a clean 1.5-ml centrifuge tube before 200 µl of eluent (preheated to 70°C) was added. The cells were kept at room temperature for 5 min and were then centrifuged at 8,000 g for 1 min to obtain the target DNA. After staining with ethidium bromide, 1% agarose gel electrophoresis and pulsed-field gel electrophoresis were used to analyze the results.
Detection of changes in the cell lipid peroxide content
During oxidative stress, a portion of the intracellular fatty acids is oxidized into a series of complex compounds, including malondialdehyde (MDA). The level of lipid oxidation can be detected by determining the MDA level. This study used an Oxltek TBARS assay kit (Zeptometrix Corporation, NY, USA). Using the colorimetric method, we performed quantitative MDA detection. First, we used 100 µl of cold PBS to suspend the cells, and then we added 100 µl of sodium dodecyl sulfate (SDS) solution. After vortex mixing, 500 µl of thiobarbituric acid (TBA)/buffer reagent (acetic acid+sodium hydroxide+TBA solution) was added. The solution was incubated at 95°C for 60 min and then chilled on ice for 10 min. The supernatant was then transferred to a 96-well plate, and an ELISA reader was used to determine the absorbance and concentration. The excitation wavelength was established at 535 nm, and the maximum emission wavelength was 553 nm.
Detection of the activity of caspase 3 and 8 apoptosis factors
A caspase 3 and 8 detection assay kit (Beyotime Institute of Biotechnology, Haimen, Jiangsu, China) was used to detect caspase activity. Caspase 3-mediated protein shear is the key enzyme in cell apoptosis, chromatin-solid contraction, DNA fragmentation and cell foaming. Caspase 3 and 8 catalyze Ac-DEVD-pNA (acetyl-Asp-Glu-Val-Asp p-nitroanilide) and Ac-IETD-pNA (acetyl-Ile-Glu-Thr-Asp-p-nitroanilide), respectively, were used to produce yellow pNA (p-nitroaniline). We detected caspase 3 and 8 activity by measuring absorbance.
Each well was inoculated with 1×106 Min6 cells, and 60 µl of lysis buffer was used to lyse the cells on ice for 15 min. The cells were centrifuged at high speed, and the supernatant was collected. The standard product was diluted to concentrations of 0, 10, 20, 50, 100 and 200 µM. Various reactants were added according to the assay kit instructions. After mixing, 10 µl of Ac-DEVD-pNA or Ac-IETD-pNA (2 mM) was added. The cells were incubated at 37°C for 60 to 120 min. A405 was determined when a color change occurred. The caspase 3 (or 8) enzyme activity unit in each unit weight of protein was calculated as follows: optical density (OD) value/protein concentration. The experiment was repeated three times.
Detection of apoptosis-related protein expression
We isolated the mitochondria and cytoplasm according to the Cell Mitochondria Isolation Kit manual (Beyotime Institute of Biotechnology, Haimen, Jiangsu, China). Cold PBS was used for washing, and the Min6 cells were collected. The number of cells in each sample was greater than 2×106. The cells were centrifuged at 200 g for 5 min and then 100 µl of mitochondria isolation reagent containing phenylmethanesulfonyl fluoride (PMSF) was added. After suspension, the cells were placed in an ice bath for 10 to 15 min and then transferred to a glass homogenizer for homogenization. Subsequently, 30–50 µl of Trypan blue staining solution was added to determine the percentage of positive (blue) cells. When the percentage was greater than 50%, the cells were centrifuged at 600 g at 4°C for 10 min. The supernatant was then transferred to another centrifuge tube and centrifuged at 11,000 g at 4°C for 10 min. The supernatant and precipitate were collected. The precipitates contained the isolated cell mitochondria. The supernatant was centrifuged at 12,000 g at 4°C for 10 min to obtain the cytoplasm proteins without mitochondria. Finally, we used Western blotting, Anti-iPLA2, Anti-cPLA2, Anti-Cytochrome C, and Anti-Smac/DIABLO (Milipore, Temecula, California, USA) to detect the expression levels of the corresponding proteins.
Detection of changes in the mitochondrial membrane potential
A reduction in the mitochondrial membrane potential is the landmark event of early cell apoptosis. When the mitochondrial membrane potential (ΔΨm) was relatively high, JC-1 accumulated in the matrix of the mitochondria to form polymers and fluoresced red. When ΔΨm was relatively low, the monomer fluoresced green. The JC-1 monomer's maximum activation wavelength is 514 nm, and the maximum emission wavelength is 529 nm. The JC-1 polymer's maximum excitation wavelength is 585 nm, and the maximum emission wavelength is 590 nm.
As described in the JC1-Mitochondrial membrane potential assay kit (Abcam, Hongkong, China) manual, the pretreated cells were collected, centrifuged at 200 g for 5 min and washed twice with ice-cold PBS; then, 100 µl of JC-1 (10 µmol/l) was added. The cells were incubated at 37°C for 30 min and centrifuged at 200 g for 5 min. They were then washed once with cold PBS. After 100 µl of cold PBS was added to generate a suspension, the cells were transferred to a 96-well plate. The ELx800 Absorbance Microplate Reader (Bio-Tek Instruments, INC. Vermont, USA) was used to read the fluorescence, and the ratio of green to red fluorescence was calculated. An increase in the proportion of green fluorescence indicated that the percentage of apoptosis was relatively high.
Detection of changes in the mitochondrial ROS content
Dihydroethidium is the most common superoxide anion fluorescence probe. After consumption by living cells, superoxide anions dehydrogenate dihydroethidium in the cell and produce ethidium. Dihydroethidium exhibits blue fluorescence with a maximum excitation wavelength of 370 nm and a maximum emission wavelength of 420 nm. After dehydrogenation, dihydroethidium combines with RNA or DNA to fluoresce red with a maximum excitation wavelength of 300 nm and a maximum emission wavelength of 610 nm. Initially, dihydroethidium (Sigma, Missouri, USA) was diluted in DMSO to prepare a 5000-µmol/l mother solution. Before detection, the mother solution was diluted to 2 µmol/L and incubated with the pretreated cells at 37°C for 15 min. The solution was then centrifuged at 200 g for 5 min, washed once with cold PBS and transferred to a 96-well plate. The ELx800 Absorbance Microplate Reader (Bio-Tek Instruments, INC. Vermont, USA) was used to read the fluorescence and detect the fluorescence ratio of blue to red. An increase in the proportion of red fluorescence indicated that the percentage of apoptosis was relatively high.
Determination of protein concentration
Under alkaline conditions, the protein reduced Cu2+ to Cu+. Cu+ and a bicinchoninic acid (BCA) reagent formed a purple complex, and its absorbance value was measured at 562 nm. The absorbance values were then compared to the standard curve to calculate the protein concentration. Pierce BCA protein assay kits (Thermo, Rockford, IL, USA) were used.
Determination of iPLA2 activity
We used a cPLA2 (Ca2+-dependent Phospholipase A2) assay kit (Cayman Chemical Company, MI, USA). cPLA2 specifically hydrolyzes arachidonic acid (sn-2 arachidonoyl thioester and thiol release). Thiol can be detected by DTNB (5,5′-dithiobis(2-nitrobenzoic acid)), and the result is equal to the total PLA2 activity. The iPLA2 blocking agent bromoenol lactone (BEL) was then added to calculate the iPLA2 content of the total PLA2 and iPLA2 activity.
Extraction of iPLA2 RNA for further analysis by RT-PCR
RNA extraction was based on the method provided by TRIZOL Reagent (Invitrogen, Florida, USA), which is divided into six steps: homogenization, phase separation, RNA precipitation, RNA washing, dissolution and RNA determination. For reverse-transcription PCR, an ImProm-II™ reverse transcription assay kit (Promega, Wisconsin, USA) was used. Based on the method provided by Promega, a 20-µl reaction volume was used to reverse-transcribe 1 µg of total RNA. This procedure was divided into two steps: RNA combination with a primer and denaturation and the reverse-transcription reaction. The iPLA2 primer sequences were designed using Primer 3 software, and the target sequences were downloaded from the GenBank database.
Sense strand: (5′- GCCCTGGCCATTCTACACAGTA-3′)
Anti-sense strand: (5′- CACCTCATCCTTCATACGGAAGT-3′)
18S sense strand: (5′- GCCGCTAGAGGTGAAATTCTTG-3′)
Anti-sense strand: (5′- CATTCTTGGCAAATGCTTTCG-3′).
SYBRGreen was used for one-step real-time quantitative PCR analysis. The internal reference gene was 18S. The analysis was divided into two steps: preparation of the reaction system and real-time quantitative PCR analysis.
Exendin-4 intervention
Exendin-4 (Taili Biological Engineering Co., Ltd. Dongguan, Guangdong, China) was added based on the induction of apoptosis at an early stage. A group intervention was performed based on time-concentration.
The following groups were used: 1) control group; 2) t-BHP group (25, 50, 100, 125, 200 and 400 µmol/l); 3) H2O2 group (50, 100 and 200 µmol/l); 4) Exendin-4 (10 and 100 nmol/l); 5) Min6 cells pretreated with Exendin-4 for 24 hours and then added to t-BHP (200 and 400 µmol/l); 6) Min6 cells pretreated with Exendin-4 for 24 hours and then added to H2O2 (50, 100 and 200 µmol/l); 7) Min6 cells pretreated with Exendin-4 for 48 hours and then added to t-BHP (200 and 400 µmol/l); and 8) Min6 cells pretreated with Exendin-4 for 48 hours and then added to H2O2 (50, 100 and 200 µmol/l).
When the cells were harvested, the occurrence of apoptosis, changes in mitochondrial membrane potential and mitochondrial generation of ROS, caspase 3 and caspase 8 activities, protein cytochrome c and Smac/DIABLO expression in mitochondria and cytoplasm, and iPLA2 expression and activity were evaluated.
Statistical analysis
SPSS 16.0 was used for the statistical analyses. The data were expressed as the means±S.D. The data were analyzed using a general linear model and repeated measures analysis of variance. p<0.05 was considered statistically significant.
Results
Optimal time-concentration intervention (200 µmol/L of t-BHP for 24 hours)
Flow cytometry was used to analyze the concentration/time gradient. The results showed that as the time and concentration increased, the rate of Min6 cell apoptosis gradually increased. These results were shown as two peaks on the concentration/time curve, representing a t-BHP concentration of 200 µmol/l for 1 and 24 hours. At the t-BHP concentration of 200 µmol/l for 1 hour, there was significant early- and late-stage apoptosis. The total rate of apoptosis ranged from 40.1 to 60%, the average early apoptosis rate was 31.55%, the late apoptosis rate was 8.46%, and the average cell mortality was 26.8%. However, as the time increased, the rate of increased apoptosis slowed. At 8 hours, the apoptosis percentage was not significantly different from that at 1 hour (p>0.05). At 200 µmol/l of t-BHP for 24 hours, the late-stage apoptosis rate was 46.1%, the early-stage apoptosis rate was 21.6%, and cell mortality was 4.86%. When the concentration reached 400 µmol/l in 1 hour, there was significant apoptosis in the Min6 cells, with more than 90% mortality (Figures 1 & 2).
Exendin-4 (100 µM for 48 hours) protects cells from mitochondrial stress–induced apoptosis
The results of incubating Min6 cells with Exendin-4 showed that as the time increased, the rate of apoptosis decreased (p<0.05). Compared with the control group, when Exendin-4 was incubated with Min6 cells for 24 hours and 200 µM t-BHP was added for 24 hours, the total apoptosis rate of the Min6 cells was reduced from 66.7 to 54.5%. When Exendin-4 was incubated with Min6 cells for 48 hours and 200 µM t-BHP was added for 24 hours, the total percentage of dead and apoptotic Min6 cells was reduced to 14.1% (Figure 3).
Using a DNA ladder assay kit, we performed a DNA fragmentation analysis according to the manufacturer's instructions. Initially, at 200 µmol/l of t-BHP for 24 hours, no typical changes in DNA fragmentation were observed. We then used 100 µmol/l of H2O2 for 24 hours. We applied an orthogonal alternating-pulse electric field in the agarose gel, and the results showed that the DNA exhibited changed fragmentation behavior. We used flow cytometry to detect the percentage of cell apoptosis. The percentage of 100-µM-H2O2-induced Min6 cell apoptosis was 79.2%. When Exendin-4 was incubated with Min6 cells for 48 hours and 100 µM H2O2 was added for 24 hours, the DNA fragmentation was attenuated, and the total percentage of dead and apoptotic Min6 cells was reduced to 56.8% (Figure 4).
An Oxltek TBARS assay kit was used to detect changes in the Min6 cell oxidative fatty acid content. The results showed that as the rate of cell apoptosis increased, the cell oxidative fatty acid content also increased in the t-BHP 100 µM 24-hour group (Figure 5). t-BHP induces an increase in the Min6 cell oxidative fatty acid content.
Exendin-4 (100 µM for 48 hours) prevents the loss of mitochondrial membrane potential
Alterations in the mitochondrial membrane potential represent an early transition in the induction of apoptosis. To determine whether Exendin-4 can prevent the loss of mitochondrial membrane potential, we found that at 100 µmol/l of t-BHP for 2 hours, the mitochondrial membrane potential began to decrease; at 24 hours, the potential loss was approximately 80%. However, after treatment with Exendin-4 (100 µM for 48 hours), the t-BHP induced membrane potential loss decreased (n = 6; p<0.05; details shown in Figure 6).
Exendin-4 (100 µM for 48 hours) protects cells from producing more ROS in response to t-BHP treatment
We examined whether Exendin-4 affects the amount of ROS generation by mitochondria response to t-BHP. We found that after treatment with 100 µmol/l of t-BHP for 2 hours, the superoxide content of the Min6 cell mitochondria increased and peaked after 8 hours. With the addition of Exendin-4 (100 µM for 48 hours), the t-BHP-induced ROS generation decreased (n = 6; p<0.05; details shown in Figure 7).
Exendin-4 attenuates the release of cell apoptotic proteins from mitochondria
Because Exendin-4 can protect mitochondrial function from ROS-inducing treatment, we examined whether it also prevent the release of cytochrome c. Western blot results showed that compared with the control, Exendin-4 (100 µM for 48 hours) reduced the expression of cytochrome c in the cytoplasm (n = 6; p<0.05; Figure 8). We also examined the mitochondrial protein Smac/DLAMO, which promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. We found that compared to the control group, Exendin-4 also attenuates the t-BHP-induced Smac/DLAMO release from the mitochondria (n = 6; p<0.05; Figure 9).
Exendin-4 (100 µM for 48 hours) reduces caspase 3 activity
The caspase 3 activity was measured using a caspase 3 activity assay kit. The results showed that as the reaction time increased at a t-BHP concentration of 200 µM, the caspase 3 expression level progressively increased. Incubation with Exendin-4 for 48 hours attenuated the accelerating increase in the expression level of caspase 3 and decreased its production. There was a statistically significant difference between the two groups (n = 6; p<0.05; Figure 10).
The caspase 8 activity was measured using a caspase 8 activity assay kit. The results showed that as the reaction time increased at a t-BHP concentration of 200 µM, the quantity of caspase 8 expression progressively increased; however, compared with the control group, there was no statistically significant difference between the control and Exendin-4 (100 µM for 48 hours) groups (p>0.05; Figure 11).
No significant correlation between cPLA2 and ROS-induced Min6 cell apoptosis
In this study, we did not observe any direct relationship between cPLA2 expression and cell apoptosis. For the t-BHP 200 µM 24-hour group, we did not observe any relationship between cPLA2 expression and Min6 cell apoptosis (Figure 12).
iPLA2 was transcriptionally downregulated in t-BHP-induced apoptosis, and Exendin-4 (100 µM 48 hour) is positively correlated with iPLA2 transcription
Exendin-4 plays an important role in the protection of mitochondria during t-BHP-induced apoptosis, and under physiological conditions, mitochondria can repair peroxidative damage in part through a remodeling mechanism via the deacylation-reacylation cycle mediated by phospholipase A2. Consequently, we investigated whether iPLA2 plays a role in protecting mitochondrial function from damage caused by mitochondrial-generated ROS during apoptotic induction by t-BHP and whether the Exendin-4 protective function is related to iPLA2.
We found that compared with the t-BHP (200 µmol/l for 24 hours) group, the group that was treated with Exendin-4 (100 µM for 48 hours) had higher t-BHP-induced iPLA2 expression (p<0.05). The magnitude of the decrease in the time-concentration curve was lower in the Exendin-4 (100 µM for 48 hours) group, and the changes were not significant after 8 hours. We also examined the H2O2 (50 µM for 24 hours) group and found that after treatment with Exendin-4 (100 µM for 48 hours), the H2O2-induced iPLA2 expression exhibited the same trend (p<0.05; Figure 13). iPLA2's activity was correlated with its protein levels (Figure 14).
To confirm that t-BHP downregulates iPLA2 transcription, we used RT-PCR to quantify iPLA2 mRNA levels in the t-BHP group and the Exendin-4 group (after treatment with Exendin-4 100 µM for 48 hours, the cells were treated with 100 µM t-BHP for 24 hours). Our results suggest that t-BHP not only induces the oxidative stress that leads to the peroxidation of mitochondrial membrane phospholipids but also impairs the repair system by downregulating iPLA2 transcription. Exendin-4 can attenuate this condition (Figure 15).
Discussion
Numerous types of chronic damage, including glucotoxicity, lipotoxicity and amylin, are important mechanisms for the progression of type 2 diabetes mellitus (T2DM). Eventually, these types of damage lead to increased pancreatic β-cell mitochondrial ROS production, mitochondrial inner membrane cardiolipin oxidative damage and pancreatic β-cell apoptosis. Previous research has shown that Exendin-4 reduces pancreatic β-cell apoptosis at the gene level, promotes pancreatic β-cell proliferation and differentiation, improves insulin resistance through numerous mechanisms, reduces metabolic damage and improves the T2DM pathological status [23]–[28].
Based on the literature published in China and overseas, we chose superoxide t-BHP and H2O2 to establish a Min6 cell oxidative damage model. The results showed that as the rate of cell apoptosis increased, the intracellular oxidative lipid content increased, which revealed that oxidative stress was the main mechanism of mitochondrial damage in Min6 cells in this study. Superoxide t-BHP- and H2O2-induced Min6 cell apoptosis showed time-concentration dependency, with two peak values at t-BHP (200 µM for 1 hour) and t-BHP (200 µM for 24 hours). This result may be related to the acute chemical injury induced by the initial effect of a strong oxidizing agent and the initiation of the cells' self-protective stress response. In the t-BHP (200 µM for 24 hours) group, the Min6 cell mitochondrial damage index (membrane potential and ROS) increased. The expression of caspase 3 and 8 apoptosis factors increased, and mitochondrial cytochrome c and apoptosis protein Smac/DLAMO were released into the cytoplasm. The results suggest that oxidative damage plays an important role in the process of pancreatic β-cell apoptosis.
The group treated with Exendin-4 (100 µM for 48 hours) showed reductions in the rate of cell apoptosis, mitochondrial ROS production, membrane potential, production of apoptosis factor caspase 3, release of mitochondrial protein cytochrome c and apoptosis protein Smac/DLAMO into the cytoplasm, and oxidative damage, compared with the t-BHP (200 µM for 1 hour) group. These results suggest that Exendin-4 has a protective role in mitochondrial function and can reduce pancreatic β-cell apoptosis.
iPLA2 is an important phospholipid remodeling and repair factor that enriches the inner mitochondrial membrane cardiolipin in polyunsaturated fatty acids through deacylation and acylation. iPLA2 allows the inner mitochondrial membrane to maintain structural completeness and normal function and makes important contributions to oxidative damage resistance. Previous research has shown that iPLA2 plays a key regulatory role in oxidative stress-induced pancreatic cell apoptosis and is closely related to the programed apoptosis of pancreatic cells [29]–[35]. In this study, before and after the addition of Exendin-4 (100 µM for 48 hours), the Min6 cell apoptosis rate was observed to be positively related to iPLA2 expression; apoptosis was reduced in Min6 cells with high levels of iPLA2 expression, and this tendency was related to Exendin-4.
Much research has been published on the anti-apoptotic mechanism of Exendin-4 in the pancreatic β-cell. The research has focused on the cAMP activation of phosphatidylinositol 3-kinase (PI3K) and its downstream mitogen-activated protein kinase (MAPK/ERK) and protein kinase B (PKB/Akt) and protein kinase A (PKA) signal transduction pathways; the regulation of caspase 3, Fas and apoptosis promoting genes, such as programmed cell apoptosis factor 5 (PDCD25); the regulation of the expression of anti-apoptotic proteins, such as Bcl-2 and Bcl-xL; the enhancement of PI3K and PKC activity; the induction of pancreatic and duodenal homeobox-1 (PDX-1) gene expression; and the induction of early cell differentiation-related genes, such as C-fox, C-jun, Jun-B, Zif-268 and Nur-77, to reduce pancreatic β-cell apoptosis. However, the exact mechanism of Exendin-4 in pancreatic β-cells remains unknown. This study is the first to use an Exendin-4 agent synthesized through biofermentation technology (the pET32a(+) plasmid and the synthetic Exendin-4 gene fragment were digested with KpnI and HindIII, and they were ligated together using a ligase to form the recombinant plasmid. The plasmid was then transformed into the BL21(DE3) E. coli strain to obtain the recombinant genetic engineering strain. After high-density fermentation, chromatography, enzyme digestion and repeated chromatography, the stock solution was obtained). Additionally, it is the first to use oxidative stress as the breakthrough point for preliminary investigations of the relationship between iPLA2's anti-oxidative mechanism and the anti-apoptotic role of Exendin-4 in pancreatic β-cells. We showed that Exendin-4 could reduce pancreatic β-cell apoptosis and mitochondrial oxidative stress and that these roles may be related to iPLA2. A direct correlation requires further research.
Acknowledgments
We are grateful to Prof. Shiping Liu and Dr. Yang Xiao for their contributions to the analysis tools and their comments on this manuscript. The Department of Diabetes Center, Second Xiangya Hospital specifically claims no responsibility for any analyses, interpretations or conclusions.
Funding Statement
This study was financial supported by the National Natural Science Foundation of China (Grant No. 81170725, 81070672, 81000316). Web site: http://www.nsfc.gov.cn/; the International Cooperation and Exchange of the National Natural Science Foundation of China (Grant No. 30831160518). Web site: http://www.nsfc.gov.cn/; the Key Project of Science and Technology Department of Hunan Province of China (2010SK2007); Hunan Provincial Natural Science Foundation of China(11JJ7005); the National Department Public Benefit (Health) Research Foundation of China(Grant No.201002002). Web site: http://www.hnst.gov.cn/. This work was also supported by Jiangsu Hengrui Pharmaceutical Joint Stock Co. grants the trial medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The Department of Diabetes Center, 2nd Xiangya Hospital specifically disclaims responsibility for any analyses, interpretations, or conclusions.
References
- 1. Lupi R, Dotta F, Marselli L, Del Guerra S, Masini M, et al. (2002) Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effect on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. Diabetes 51: 1437–1442. [DOI] [PubMed] [Google Scholar]
- 2. Piro S, Anello M, Di Pietro C, Lizzio MN, Patanè G, et al. (2002) Chronic exposure to free fatty acid or high glucose induces apoptosis in rat pancreatic islets: possible role of oxidative stress. Metabolism 51: 1340–1347. [DOI] [PubMed] [Google Scholar]
- 3. Ritzel RA, Butler AE, Rizza RA, Veldhuis JD, Butler PC (2006) Relationship between β-cell mass and fasting blood glucose concentration in humans. Diabetes Care 29: 717–718. [DOI] [PubMed] [Google Scholar]
- 4. Butler AE, Janson J (2003) β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52: 102–110. [DOI] [PubMed] [Google Scholar]
- 5. Orrenius S (2004) Mitochondrial regulation of apoptotic cell death. Toxicol Lett 149 (3) 19–23. [DOI] [PubMed] [Google Scholar]
- 6. Schlame M, Rua D, Greenberg ML (2000) The biosynthesis and functional role of cardiolipin. Prog Lipid Res 39: 257–288. [DOI] [PubMed] [Google Scholar]
- 7. Mileykovskaya E, Zhang M, Dowhan W (2005) Cardiolipin in Energy Transducing Membranes. Biochemistry (Moscow) 70: 154–158. [DOI] [PubMed] [Google Scholar]
- 8. Molina AJ, Wikstrom JD, Stiles L, Las G, Mohamed H, et al. (2009) Mitochondrial networking protects β-cells from nutrient-induced apoptosis. Diabetes 58: 2303–2315. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Wiswedel I, Gardemann A, Storch A, Peter D, Schild L (2010) Degradation of phospholipids by oxidative stress—exceptional significance of cardiolipin. Free Radic Res 44 (2) 135–145. [DOI] [PubMed] [Google Scholar]
- 10. Schlame M, Rustow B (1990) Lysocardiolipin formation and reacylation in isolated rat liver mitochondria. Biochem 272: 589–595. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Winstead MV, Balsinde J, Dennis EA (2000) Calcium-independent phospholipase A 2: structure and function. Biochim Biophys Acta 1488: 28–39. [DOI] [PubMed] [Google Scholar]
- 12. Williams SD, Gottlieb RA (2002) Inhibition of mitochondrial calcium-independent phospholipase A2 (iPLA2) attenuates mitochondrial phospholipid loss and is cardioprotective. Biochem 362: 23–32. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Ma Z, Ramanadham S, Wohltmann M, Bohrer A, Hsu FF, et al. (2001) Studies of insulin secretory responses and of arachidonic acid incorporation into phospholipids of stably transfected insulinoma cells that overexpress group VIA phospholipase A2 (iPLA2beta) indicate a signaling rather than a housekeeping role for iPLA2beta. J Biol Chem 276: 131198–131208. [DOI] [PubMed] [Google Scholar]
- 14. Six DA, Dennis EA (2000) The expanding superfamily of phospholipase A (2) enzymes: classification and characterization. Biochim Biophys Acta 1488: 1–19. [DOI] [PubMed] [Google Scholar]
- 15. Seleznev K, Zhao C, Zhang XH, Song K, Ma ZA (2006) Calcium-independent phospholipase A2 localizes in and protects mitochondria during apoptotic induction by staurosporine. J Biol Chem 281 (31) 22275–22288. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Copley K, McCowen K, Hiles R, Nielsen LL, Young A, et al. (2006) Investigation of exenatide elimination and its in vivo and in vitro degradation. Curr Drug Metab 7 (4) 367–374. [DOI] [PubMed] [Google Scholar]
- 17. Chen J, Couto FM, Minn AH, Shalev A (2006) Exenatide inhibits β-cell apoptosis by decreasing thioredoxin interacting protein. Biochem Biophys Res Commun 346 (3) 1067–1074. [DOI] [PubMed] [Google Scholar]
- 18. Li YZ, Hansotia TY, Yusta B, Ris F, Halban PA, et al. (2003) Glucagon-like pep tide-1 receptor signaling modulates β-cell apoptosis. J Biol Chem 278 (1) 471–478. [DOI] [PubMed] [Google Scholar]
- 19. Wang Y, Egan JM, Raygada M, Nadiv O, Roth J, et al. (1995) Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells. Endocrinology 136 (11) 4910–4917. [DOI] [PubMed] [Google Scholar]
- 20. Li Y, Cao X, Li LX, Brubaker PL, Edlund H, et al. (2005) Beta-cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. Diabetes 54 (2) 482–491. [DOI] [PubMed] [Google Scholar]
- 21. Bulotta A, Hui H, Anastasi E, Bertolotto C, Boros LG, et al. (2002) Cultured pancreatic ductal cells undergo cell cycle re-distribution and beta-cell like differentiation in response to glucagon-like peptide-1. J Mol Endocrinol 29 (3) 347–360. [DOI] [PubMed] [Google Scholar]
- 22. Holst J (2007) The physiology of glucagon like peptide 1. Physiol Rev 87: 1409–1439. [DOI] [PubMed] [Google Scholar]
- 23. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, et al. (1996) Glucagonostatic action and reduction of fasting hyperglycemia by exogenous glucagon-like peptide (7–36) amide in type 1 diabetic patients. Diabetes care 19 (6) 580–586. [DOI] [PubMed] [Google Scholar]
- 24.U.S. Food and Drug Administration website. Available: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM191084.pdf. Medication guide, Byetta. Accessed 2013 August 29.
- 25. Monami M, Marchionni N, Mannucci E (2009) Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol 160 (6) 909–917. [DOI] [PubMed] [Google Scholar]
- 26. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, et al. (2005) Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 143 (8) 559–569. [DOI] [PubMed] [Google Scholar]
- 27. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, et al. (2005) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28 (5) 1083–1091. [DOI] [PubMed] [Google Scholar]
- 28. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, et al. (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28 (5) 1092–1100. [DOI] [PubMed] [Google Scholar]
- 29. Song K, Zhang X, Zhao C, Ang NT, Ma ZA (2005) Inhibition of Ca2+-independent phospholipase A2 results in insufficient insulin secretion and impaired glucose tolerance. Mol Endocrinol 19 (2) 504–515. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Smani T, Zakharov SI, Csutora P, Leno E, Trepakova ES, et al. (2004) A novel mechanism for the store-operated calcium influx pathway. Nat Cell Biol 6 (2) 113–120. [DOI] [PubMed] [Google Scholar]
- 31. Li J, Romestaing C, Han X, Li Y, Hao X, et al. (2010) Cardiolipin remodeling by ALCAT1 links oxidative stress and mitochondrial dysfunction to obesity. Cell Metab 12 (2) 154–165. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Widlansky ME, Wang J, Shenouda SM, Hagen TM, Smith AR, et al. (2010) Altered mitochondrial membrane potential, mass, and morphology in the mononuclear cells of humans with type 2 diabetes. Transl Res 156 (1) 15–25. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Chicco AJ, Sparagna GC (2007) Role of cardiolipin alterations in mitochondrial dysfunction and disease. Am J Physiol Cell Physiol 292 (1) C33–44. [DOI] [PubMed] [Google Scholar]
- 34. Gonzalvez F, Gottlieb E (2007) Cardiolipin: setting the beat of apoptosis. Apoptosis 12: 877–885. [DOI] [PubMed] [Google Scholar]
- 35. Zhao Z, Zhang X, Zhao C, Choi J, Shi J, et al. (2010) Protection of pancreatic {beta}-cells by group VIA phospholipase A2-mediated repair of mitochondrial membrane peroxidation. Endocrinology 151 (7) 3038–3048. [DOI] [PMC free article] [PubMed] [Google Scholar]